Global pharmaceutical company Merck (NYSE:MRK) will be reporting results this Tuesday before the bell. Here’s what you need to know.

Merck (MRK) ’s stock surged by 41% in the last six months, driven not only by a modest revenue increase but also by a ...

Merck (MRK) closed at $110.42 in the latest trading session, marking a +1.92% move from the prior day. The stock outperformed ...

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

The company’s previous CCO was Cristal Downing, who joined Insulet as chief corporate affairs officer late last year.

By Arasu Kannagi Basil Jan 28 (Reuters) - Eikon ‍Therapeutics, headed by Merck veteran Roger Perlmutter, is targeting a valuation of up to $908.2 million in its initial public offering in the United ...

The pharmaceutical giant had been in talks to buy the cancer drug developer in a transaction that could have valued ...

On January 27, Cantor Fitzgerald boosted its price target on Merck & Co., Inc. (NYSE:MRK) to $116 from $83 but kept its ...

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...

Guardant Health is signing up to a multiyear deal with Merck & Co. for the U.S. Big Pharma to tap its Infinity Smart platform ...

Jan 25 (Reuters) - Merck is no longer in discussions to buy cancer drug developer Revolution Medicines, the Wall Street ...

It was revealed in a recent SEC filing that Chirfi Guindo, Chief Marketing Officer at Merck & Co (NYSE: MRK) made a ...